Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

H3K27me3 and H3K4me3 ChIP-seq on DMSO and EPZ6438 treated CD34+ HSPCs

ABSTRACT: H3K27me3 and H3K4me3 ChIP-seq on DMSO and EPZ6438 treated CD34+ HSPCs

PROVIDER: PRJNA602858 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10957028.fastq.gz	Fastqsanger.gz
	SRR10957029.fastq.gz	Fastqsanger.gz
	SRR10957030.fastq.gz	Fastqsanger.gz
	SRR10957031.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

RNA-seq on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:RNA-seq on DMSO and EPZ6438 treated CD34+ HSPCs

| PRJNA602869 | ENA

In Situ on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:In Situ on DMSO and EPZ6438 treated CD34+ HSPCs

| PRJNA602860 | ENA

H3K27me3 and H3K4me3 ChIP-seq on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:The overall goal is to understand how does the DNA methylation Canyon interactions in CD34+ HSPCs can be impacted by the inhibition of EZH2

2020-01-24 | GSE144124 | GEO

RNA-seq on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:The overall goal is to understand how does the DNA methylation Canyon interactions in CD34+ HSPCs can be impacted by the inhibition of EZH2

2020-01-24 | GSE144131 | GEO

In Situ on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:The overall goal is to understand how does the DNA methylation Canyon interactions in CD34+ HSPCs can be impacted by the inhibition of EZH2

2020-01-24 | GSE144126 | GEO

Population RNA Seq of human HSPCs (Lineage negative, CD38 negative, CD34 positive) of control patients or myocardial infarction patients and treated with at-RA/4-oxo-RA/DMSO for 72h in culture

Project description:Study of the transcriptomic changes in human HSPCs under the influence of at-RA and 4-oxo-RA. Human Hematopoietic Stem and Progenitor Cells (HSPCs)(Lineage negative, CD38 negative, CD34 positive cells) were isolated from sternal bone marrow of patients who had experienced myocardial infarction or from control patients. For in vitro cultivation, cells were treated with at-RA (2.5 μM final concentration), 4-oxo-RA (2.5 μM final concentration), or the respective volume of DMSO (control) for 72 hours. After incubation period, cells were harvested for RNA extraction.

2025-02-06 | E-MTAB-13508 | biostudies-arrayexpress

DARTseq identifies m6A targets in human CD34+ HSPCs

Project description:The goal of this study is to identify m6A targets in human CD34+ HSPCs with or without STM2457 treatment using DARTseq. Purified human CD34+ HSPC cells were transduced with APOBEC-YTH or empty vector control (MIG). 24hr post infection, CD34+ cells were treated with STM2457 at a concentration of 20µM for 2 days. GFP+ cells were sorted the next day. 3 replicates were performed.

2023-12-07 | GSE231861 | GEO

Homo sapiens isolate:CD34+ HSPCs

Project description:Off-target deep sequencing of FLT3, CD123, KIT epitope-edited CD34+ HSPCs

| PRJNA986845 | ENA

Transcriptome of CBX7 and CBX8 overexpressing CD34+ HSPCs

Project description:Transcriptome of CBX7 and CBX8 overexpressing CD34+ HSPCs

| PRJEB22831 | ENA

DARTseq identifies m6A targets in human CD34+ HSPCs

Project description:DARTseq identifies m6A targets in human CD34+ HSPCs

| PRJNA968169 | ENA